Catalogue

COVID-19: Updates on library services and operations.

Policy issues in the development of personalized medicine in oncology [electronic resource] : workshop summary /
Margie Patlak and Laura Levit, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National Academies.
imprint
Washington, D.C. : National Academies Press, c2010.
description
xii, 82 p. : ill. 23 cm.
ISBN
0309145759 (pbk.), 9780309145756 (pbk.)
format(s)
Book
Holdings
More Details
imprint
Washington, D.C. : National Academies Press, c2010.
isbn
0309145759 (pbk.)
9780309145756 (pbk.)
restrictions
Licensed for access by U. of T. users.
contents note
Personalized cancer medicine technology -- Regulation of predictive tests -- Reimbursement.
general note
" ... the National Cancer Policy Forum held a workshop, "Policy Issues in the Development of Personalized Medicine in Oncology," in Washington, DC, on June 8 and 9, 2009."--P. 1.
abstract
"One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop."--Publisher's description.
catalogue key
11512040
 
Includes bibliographical references (p. 65-70).
A Look Inside
Reviews
This item was reviewed in:
Reference & Research Book News, June 2011
To find out how to look for other reviews, please see our guides to finding book reviews in the Sciences or Social Sciences and Humanities.
Summaries
Description for Bookstore
One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncologyin June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop.
Long Description
One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop.
Main Description
" ... the National Cancer Policy Forum held a workshop, "Policy Issues in the Development of Personalized Medicine in Oncology," in Washington, DC, on June 8 and 9, 2009."--P. 1.
Table of Contents
Introductionp. 1
Personalized Cancer Medicine Technologyp. 3
Deciphering the Clinical Implicationsp. 6
Increasing Complexity of Predictive Testsp. 9
Test Validationp. 15
Test Reliabilityp. 19
Translation Challengesp. 21
Codevelopment Challengesp. 23
Regulation of Predictive Testsp. 25
Overview of the FDA's Regulation of Predictive Testsp. 25
Overview of CMS's Regulation of Laboratories Performing Predictive Testsp. 28
Should the FDA Do More?p. 30
Is the Status Quo Appropriate?p. 33
Policy Suggestionsp. 36
Improve Laboratory Proficiencyp. 37
Increase Transparencyp. 38
Restructure and Coordinate Oversightp. 39
Improve Enforcementp. 40
Assess Clinical Utilityp. 41
Ways to Capture Clinical Utility Datap. 43
Reimbursementp. 49
Medicare Coverage of Predictive Testsp. 49
Reimbursement Ratesp. 52
Bundling of Paymentsp. 54
Value of Biomarkersp. 56
Summaryp. 63
Referencesp. 65
Acronymsp. 71
Glossaryp. 73
Appendixes
Workshop Agendap. 77
Workshop Speakers and Moderatorsp. 81
Table of Contents provided by Ingram. All Rights Reserved.

This information is provided by a service that aggregates data from review sources and other sources that are often consulted by libraries, and readers. The University does not edit this information and merely includes it as a convenience for users. It does not warrant that reviews are accurate. As with any review users should approach reviews critically and where deemed necessary should consult multiple review sources. Any concerns or questions about particular reviews should be directed to the reviewer and/or publisher.

  link to old catalogue

Report a problem